JO3544B1 - عامل علاجي للاختلال الوظيفي في الفص الجبهي - Google Patents

عامل علاجي للاختلال الوظيفي في الفص الجبهي

Info

Publication number
JO3544B1
JO3544B1 JOP/2016/0045A JOP20160045A JO3544B1 JO 3544 B1 JO3544 B1 JO 3544B1 JO P20160045 A JOP20160045 A JO P20160045A JO 3544 B1 JO3544 B1 JO 3544B1
Authority
JO
Jordan
Prior art keywords
cognitive impairment
disease
frontal lobe
dementia
therapeutic agent
Prior art date
Application number
JOP/2016/0045A
Other languages
English (en)
Inventor
Horita Takako
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Application granted granted Critical
Publication of JO3544B1 publication Critical patent/JO3544B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير عامل علاجي و/أو وقائي، على سبيل المثال، للخلل الوظيفي بالفص الجبهي (على سبيل المثلا، قصور إدراكي (على سبيل المثال، قصور إدراكي في مرض باركينسون، قصور إدراكي ناجم عن إجهاد مزن، الخرف بأجسام ليوي، شلل فوق النوى مترقي، الخرف الجبهي الصدغي وما شابه) وما شابه)، مرض جسم ليوي ( على سبيل المثال، قصور إدراكي في مرض باكينسون، مرض جسم ليوي منتشر، الخرف بأجسام ليوي، اضطراب حركي مرتبط بمرض جسم ليوي وما شابه) وما شابه، الذي يتضمن مركب ممثل بالصيغة (<span dir="LTR">I</span>) أو ملح مقبول صيدلانية منه في صورة مكون فعال.
JOP/2016/0045A 2015-03-19 2016-03-17 عامل علاجي للاختلال الوظيفي في الفص الجبهي JO3544B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015055532 2015-03-19

Publications (1)

Publication Number Publication Date
JO3544B1 true JO3544B1 (ar) 2020-07-05

Family

ID=56919157

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0045A JO3544B1 (ar) 2015-03-19 2016-03-17 عامل علاجي للاختلال الوظيفي في الفص الجبهي

Country Status (38)

Country Link
US (2) US20180042910A1 (ar)
EP (1) EP3270923B1 (ar)
JP (1) JP6869893B2 (ar)
KR (1) KR20170129764A (ar)
CN (1) CN107405341A (ar)
AR (1) AR103972A1 (ar)
AU (1) AU2016234211B2 (ar)
BR (1) BR112017018165A2 (ar)
CA (1) CA2978426A1 (ar)
CL (1) CL2017002351A1 (ar)
CO (1) CO2017008814A2 (ar)
CR (1) CR20170405A (ar)
CY (1) CY1124459T1 (ar)
DK (1) DK3270923T3 (ar)
DO (1) DOP2017000206A (ar)
EA (1) EA032511B1 (ar)
EC (1) ECSP17069712A (ar)
ES (1) ES2884846T3 (ar)
GE (2) GEP20197007B (ar)
HR (1) HRP20211340T1 (ar)
HU (1) HUE055387T2 (ar)
IL (1) IL254196A0 (ar)
JO (1) JO3544B1 (ar)
LT (1) LT3270923T (ar)
MX (1) MX381277B (ar)
MY (1) MY196076A (ar)
PE (1) PE20171621A1 (ar)
PL (1) PL3270923T3 (ar)
PT (1) PT3270923T (ar)
RS (1) RS62311B1 (ar)
SG (1) SG11201707012YA (ar)
SI (1) SI3270923T1 (ar)
SV (1) SV2017005527A (ar)
TN (1) TN2017000369A1 (ar)
TW (1) TWI723012B (ar)
UA (1) UA123578C2 (ar)
WO (1) WO2016148308A1 (ar)
ZA (1) ZA201706136B (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113016719B (zh) * 2019-12-24 2022-08-02 复旦大学附属华山医院 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
JP4638355B2 (ja) 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers

Also Published As

Publication number Publication date
HRP20211340T1 (hr) 2021-11-26
HUE055387T2 (hu) 2021-11-29
CN107405341A (zh) 2017-11-28
CR20170405A (es) 2018-01-30
HK1249059A1 (zh) 2018-10-26
AU2016234211A1 (en) 2017-10-12
ES2884846T3 (es) 2021-12-13
JP6869893B2 (ja) 2021-05-12
UA123578C2 (uk) 2021-04-28
SI3270923T1 (sl) 2021-10-29
EA201792070A1 (ru) 2018-01-31
US20180042910A1 (en) 2018-02-15
AU2016234211B2 (en) 2020-08-27
PL3270923T3 (pl) 2021-12-20
BR112017018165A2 (pt) 2018-04-10
TN2017000369A1 (en) 2019-01-16
PE20171621A1 (es) 2017-11-02
SV2017005527A (es) 2017-10-23
GEP20197007B (en) 2019-07-25
PT3270923T (pt) 2021-08-26
ECSP17069712A (es) 2018-02-28
ZA201706136B (en) 2019-01-30
US20210393606A1 (en) 2021-12-23
EP3270923A4 (en) 2018-11-07
MX2017012020A (es) 2018-01-30
AR103972A1 (es) 2017-06-14
SG11201707012YA (en) 2017-09-28
EA032511B1 (ru) 2019-06-28
IL254196A0 (en) 2017-10-31
MY196076A (en) 2023-03-13
TWI723012B (zh) 2021-04-01
JP2018508540A (ja) 2018-03-29
CA2978426A1 (en) 2016-09-22
CL2017002351A1 (es) 2018-03-16
DK3270923T3 (da) 2021-08-23
RS62311B1 (sr) 2021-09-30
EP3270923B1 (en) 2021-05-26
CY1124459T1 (el) 2022-07-22
LT3270923T (lt) 2021-09-10
MX381277B (es) 2025-03-12
EP3270923A1 (en) 2018-01-24
TW201705957A (zh) 2017-02-16
KR20170129764A (ko) 2017-11-27
CO2017008814A2 (es) 2018-01-16
GEAP201914604A (en) 2019-02-25
DOP2017000206A (es) 2017-12-31
WO2016148308A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
PH12016501813B1 (en) 1,3-benzodioxole derivative
GEAP202014954A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
MX2020012989A (es) Agente terapeutico para la fibrosis.
TN2016000489A1 (en) Carboxamide derivatives.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
CY1124459T1 (el) Θεραπευτικος παραγοντας για δυσλειτουργια του μετωπιαιου λοβου
MY196425A (en) Indazole Compounds For Use In Tendon And/Or Ligament Injuries
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
MX391727B (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina.
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
JP2018508540A5 (ar)
EP2924024A3 (en) Solid forms of lorcaserin hydrochloride
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
LV14852A (lv) Triazolilpur&amp;imacr;na atvasin&amp;amacr;jumi k&amp;amacr; pretv&amp;imacr;rusu prepar&amp;amacr;ti